For centuries in parts of Southeast Asia, laborers have chewed fresh leaves of the Mitragyna speciosa tree—better known as kratom—to stay productive through long, physically demanding days. Today, as powdered leaf, teas and extracts spread far beyond their traditional roots, researchers are racing to understand whether kratom’s reputation for easing pain, lifting mood and helping with drug withdrawal can withstand scientific scrutiny. While regulators including the U.S. Food and Drug Administration (FDA) stress that kratom is not approved for any medical use, a growing body of academic work is beginning to map out where its potential benefits may lie and where its risks clearly begin.
Kratom’s pharmacology is complex. The plant’s main alkaloids, mitragynine and 7-hydroxymitragynine, interact with several receptor systems in the brain, including opioid receptors, but they appear to act differently from classical opioids such as morphine. A critical review published in the journal Food and Chemical Toxicology in 2024 concluded that kratom preparations—including leaves, teas, powders, capsules and extracts—can produce stimulant effects at lower doses and analgesic, opioid-like effects at higher doses, and that current evidence indicates kratom may have therapeutic potential in some people while presenting “few risks with typical, non-polysubstance use.” Readers can examine the scope of this review directly via the article indexed on PubMed, the U.S. National Library of Medicine’s database of biomedical literature.
Perhaps the most robust evidence for kratom’s benefits so far comes from its impact on pain. In 2020, researchers conducted a randomized, placebo-controlled trial in Malaysia to test whether kratom, consumed as a traditional decoction, could increase pain tolerance in regular users. The study, published in the journal Drug and Alcohol Dependence and accessible as a full report via the U.S. National Institutes of Health’s open archive at PubMed Central, found a substantial and statistically significant rise in pain tolerance after participants drank kratom compared with a placebo beverage. Importantly, the authors reported no serious adverse effects during the short trial window and no signs of acute withdrawal during 10 to 20 hours of kratom discontinuation, though they cautioned that longer-term safety remains understudied.
Those findings fit into a broader pattern emerging in the literature. A 2023 clinical review of kratom’s therapeutic implications, also available through NIH’s PubMed Central, examined both preclinical experiments and human data. The authors reported that in animal models, kratom alkaloids produce analgesic and antinociceptive effects, meaning they increase the threshold at which painful stimuli are perceived, and that in humans, preliminary clinical data—including the randomized trial—support the idea that kratom can function as an analgesic. The same review emphasized that these benefits have been observed mostly in existing kratom consumers, not in kratom-naïve patients being treated in conventional pain clinics, underscoring how early this research field still is.
Beyond pain, millions of people now report using kratom to help manage mood and energy, as well as symptoms related to substance use. A large ecological momentary assessment study published in 2024 followed thousands of real-world kratom “use events” over 15 days to see how users rated their mood, pain, sleep and other outcomes in the hours after consuming kratom. The study, described in detail in a paper indexed on PubMed, found that participants frequently reported short-term improvements in pain and mood after use, and many cited reasons such as “relief of negative mood,” “increased energy” and “relief of withdrawal symptoms” as primary motivations for taking the plant. Because this was observational research without a placebo control, the authors were careful not to claim proof of efficacy, but the pattern of reported benefits was strikingly consistent.
Epidemiological and survey-based work, though inherently less precise than controlled trials, paints a similar picture. The U.S. National Institute on Drug Abuse notes that “many people who use kratom products report doing so to self-treat pain, anxiety, depression, fatigue and drug cravings and withdrawal symptoms,” while also stressing that researchers have not proven kratom to be safe or effective for any medical purpose and that no kratom-based product is approved by the FDA. Those dual realities are laid out in NIDA’s public fact sheet on kratom, which is available on the agency’s website at nida.nih.gov and reflects the U.S. government’s current, cautious summary of the science.
The strongest and most intensively debated potential benefit concerns kratom’s role in managing symptoms of opioid withdrawal and dependence. Case reports going back more than a decade have described individuals using kratom teas to blunt the severe withdrawal associated with prescription opioids and heroin. In one widely cited case published in The American Journal on Addictions and available through PubMed Central, a man with long-standing opioid use disorder reported that kratom dramatically reduced his withdrawal symptoms and provided meaningful pain relief, though he later developed his own dependence on kratom. Broader reviews, such as the 2023 NIH-backed clinical overview, note that observational data from Southeast Asia suggest kratom may function as a form of harm reduction, with users reporting reduced heroin or methamphetamine consumption and fewer high-risk behaviors when substituting kratom for more dangerous drugs.
However, the scientific and regulatory community remains sharply divided on how to weigh these self-reported benefits against potential risks. The FDA has repeatedly warned consumers not to use kratom products, arguing that available evidence does not meet the threshold needed to consider the substance safe or effective as a drug, dietary supplement or food ingredient. In a detailed public health advisory updated in 2025, the agency reiterates that kratom is not lawfully marketed in the United States as a drug, supplement or conventional food and expresses serious concerns about toxicity, contamination, and the risk of abuse and dependence; that position is set out in plain language on the FDA’s own information page, “FDA and Kratom,” hosted at fda.gov.
Part of the difficulty for regulators is that kratom’s risk profile appears to depend heavily on context: dosage, frequency, product type and whether it is used alongside other substances. A 2024 critical review of beneficial and adverse health effects in Food and Chemical Toxicology concluded that while many kratom products seem to present relatively low risks in typical users who are not mixing multiple drugs, serious adverse events, including toxicity and death, are far more likely to occur in the setting of polysubstance use or when highly concentrated extracts are involved. That nuanced assessment is available to clinicians and policymakers through its abstract and metadata listing on the PubMed database, which also highlights the lack of robust dose–response data for humans.
Public health surveillance underscores that context matters. A 2019 analysis by the U.S. Centers for Disease Control and Prevention of unintentional overdose deaths in 27 states found that kratom was detected in fewer than 1 percent of cases, and that in most of those deaths, other substances including prescription opioids, heroin, fentanyl or benzodiazepines were also present. The CDC’s Morbidity and Mortality Weekly Report on kratom-positive overdose deaths, which can be read in full at cdc.gov, concluded that although kratom was rarely the only substance detected, its role in complex overdoses and its interaction with other drugs warranted ongoing monitoring and further research.
International bodies are also grappling with kratom’s ambiguous status. In 2021, the World Health Organization’s Expert Committee on Drug Dependence conducted a pre-review of kratom and its main alkaloids to consider whether they should be placed under international control. After examining data on both harms and potential benefits, the committee decided against recommending a critical review—a move that would have been a step toward global scheduling—while calling for continued surveillance and data collection. While the WHO’s full technical reports are dense, summaries of the decision and its rationale have been reported by regulatory-focused publications, and the organization’s broader framework for assessing substances can be explored on its official site at who.int, which hosts guidelines and meeting records for the Expert Committee.
In the mental health realm, the evidence is even more preliminary but no less intriguing. Research teams in Southeast Asia and the United States are beginning to map how kratom use correlates with symptoms of anxiety and depression, particularly among people who use other drugs. One 2025 network analysis published in a peer-reviewed journal used statistical modeling to explore relationships between kratom consumption and mood symptoms in people who use methamphetamine, finding patterns consistent with the commonly reported anxiolytic and antidepressant effects of kratom but stopping short of establishing causation. The abstract and methodological details of this kind of work are available to specialists through journal platforms such as Taylor & Francis, which hosts the article “A network analysis of depression, anxiety, and their associations with kratom use” at tandfonline.com.
For everyday users, these emerging data points tend to reinforce what they already believe: that kratom can, at least for some people, provide real relief from chronic pain, low mood, fatigue or cravings when other options have failed. But scientists and regulators consistently emphasize that self-reported benefit is not the same as demonstrated safety and efficacy in clinical trials. As the Mayo Clinic notes in its own consumer-facing article titled “Kratom: Unsafe and ineffective,” available at mayoclinic.org, there is a significant gap between anecdotal experience and the kind of rigorous evidence needed to support medical use, and there are well-documented risks including dependence, withdrawal symptoms, and potentially serious side effects.
Still, the landscape is shifting as more targeted research gets underway. Ongoing and recently completed studies listed at ClinicalTrials.gov, the U.S. government’s registry of clinical research, aim to capture real-time data on kratom use, mood, pain and function in everyday life and to track signs of kratom use disorder. That work, combined with laboratory studies dissecting kratom’s receptor activity and metabolism, may eventually clarify how its benefits can be harnessed—if they can be—while minimizing harm. For now, the consensus among mainstream health authorities is that while kratom clearly has physiological effects and genuine potential benefits reported by users, it remains an unapproved, understudied substance whose risks and rewards are still being mapped in real time.
In practical terms, that leaves consumers, clinicians and policymakers navigating a gray zone. On one side are people who say kratom has allowed them to return to work, manage chronic pain or step back from more dangerous drugs; on the other are regulators who see an unregulated marketplace selling variable, sometimes contaminated products with limited quality control and a nontrivial risk of toxicity. Anyone considering kratom for self-treatment of pain, mental health symptoms or withdrawal is urged by agencies such as NIDA, the CDC and the FDA to weigh these uncertainties carefully, consult healthcare professionals and watch for emerging, peer-reviewed evidence. Until that evidence base matures, kratom will remain both a promising and a problematic plant—its proven benefits real but tightly circumscribed by a scientific record that is still in its early chapters.